Orexo
Manufacturing · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
PO Box Orexo Ab 303, Uppsala, Uppsala, 7...Phone Number
+46 187808800Website
www.orexo.comRevenue
$62.3 MillionStock Symbol
ORXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Orexo
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. Orexo AB was established in 1995 and is headquartered in Uppsala, Sweden.Explore more
Orexo Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orexo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Orexo had a recent Job posting/layoffs
Check if Orexo has recently received funding, and reach out quickly before it becomes old news!
Check out if Orexo is spiking on competitors!
Funding: Get notified immidiatlly once Orexo has new funding data
Earning: See what the market has to say on Orexo recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Orexo
Product Launch: Get notified when Orexo launches new products
Orexo, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Orexo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orexo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orexo.
Orexo financials insights
Gather financial insights about Orexo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series B
$22.4M
2005
Stock Offering
$35.7M
2013
Debt
$30M
2014
Debt
$53.6M
Orexo Tech Stack
A closer look at the technologies used by Orexo
See more technologies
Most Recent Scoops
Project
Orexo has announced that its OX390 project the only known program developing an overdose treatment addressing xylazine (tranq) and methadone combined with fentanyl is attracting interest from BARDA, other US authorities, and at the White House level, gaining bipartisan political traction in the US.
Medical Research, Pharmaceuticals
Earnings
Orexo has reported OPEX of SEK 107 million for the quarter, up from Q1 of the prior year, primarily driven by a SEK 20 million settlement with GAIA terminating the digital mental health collaboration, increased legal fees related to the DOJ investigation, and higher R&D costs for OX640 and OX390, partially offset by SEK 4.5 million in BARDA reimbursements and lower marketing costs for Izipry.
Earnings, Settlement, Finance
Earnings
Orexo has reported net revenues of SEK 3.5 million for the quarter, reflecting lower Abstral royalties due to expiring country-level agreements and Middle East market disruption, lower Edluar royalties following generic product launches in Canada, and higher ZUBSOLV ex-US royalties driven by a positive true-up of Q1 royalties.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Orexo has reported a total negative cash flow from continued operations of SEK 98 million in Q2, primarily driven by negative operating earnings and payments of outstanding ZUBSOLV rebate provisions, with remaining rebate payments of SEK 3 million expected to be fully phased out by year end.
Earnings, Finance
Project
Pharmaceuticals
Orexo News & Media
Orexo announces positive outcome from an in-vivo study of OX390
UPPSALA, Sweden, May 19, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo's AmorphOX® drug delivery technology. The study results mark an...Invitation & Agenda: Orexo R&D Day on March 24
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The event will take place at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan...Invitation & Agenda: Orexo R&D Day on March 24
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The event will take place at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan...Orexo changes the organizational structure and management team to increase focus on development of new products
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team. The changes are a result of the divestment of Zubsolv® in the US market and focus on advancing development programs and...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orexo
Sign Up For FreeTo access detailed company insights
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. Orexo AB was established in 1995 and is headquartered in Uppsala, Sweden.... Read More
